termsTerm
CL2A
CL2A is the deliberately fragile linker in Trodelvy: it releases SN-38 in the acidic tumour environment as well as inside cells, feeding the bystander effect.
CL2A is a pH-sensitive, hydrolysable linker with a short polyethylene glycol spacer. It releases roughly half its payload within a day in plasma, which would be a flaw for a more potent payload but suits moderately potent SN-38 at a very high drug-to-antibody ratio. The result is payload release both inside targeted cells and in the tumour microenvironment.
Category
ADC chemistry
Pages like this
not linked directly; found by shared links- IdeaTumour-on-a-chip with blood flow to test whether big drugs actually get in
Shares Bystander effect (ADC), Sacituzumab govitecan, Antibody-drug conjugate (ADC).
- Termmc-Val-Cit-PABC
Shares Linker (ADC), Bystander effect (ADC), Antibody-drug conjugate (ADC).
- TermSMCC (thioether, non-cleavable)
- TermSulfo-SPDB (disulfide)
- TermMaleimidocaproyl (mc), non-cleavable
- TermAcid-labile hydrazone (AcBut)
- TermVal-Ala dipeptide
- TermHydrophilic next-generation linkers (TMALIN, Dolaflexin, sulfonyl-pyrimidine, PEG-containing)